Neuromyelitis Optica
Symptoms, Doctors, Treatments, Advances & More

Learn About Neuromyelitis Optica

What is the definition of Neuromyelitis Optica?

Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

What are the causes of Neuromyelitis Optica?

No genes associated with neuromyelitis optica have been identified. However, a small percentage of people with this condition have a family member who is also affected, which indicates that there may be one or more genetic changes that increase susceptibility. It is thought that the inheritance of this condition is complex and that many environmental and genetic factors are involved in the development of the condition.

How prevalent is Neuromyelitis Optica?

Neuromyelitis optica affects approximately 1 to 2 per 100,000 people worldwide. Women are affected by this condition more frequently than men.

Is Neuromyelitis Optica an inherited disorder?

Neuromyelitis optica is usually not inherited. Rarely, this condition is passed through generations in families, but the inheritance pattern is unknown.

Who are the top Neuromyelitis Optica Local Doctors?
Elias Sotirchos
Elite in Neuromyelitis Optica
Elite in Neuromyelitis Optica

Johns Hopkins Outpatient Center

Baltimore, MD 
Languages Spoken:
English, Greek
Offers Telehealth

Elias Sotirchos, M.D., specializes in the diagnosis, management and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents. Dr. Sotirchos earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his internship and neurology residency training at The Johns Hopkins Hospital. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National MS Society Sylvia Lawry Fellow. Dr. Sotirchos is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. His top areas of expertise are Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis.

Distinguished in Neuromyelitis Optica
Distinguished in Neuromyelitis Optica

Vanderbilt Medical Group- Teleneurology

1161 21st Ave South, A-0118 Medical Center North, 
Nashville, TN 
Languages Spoken:
English
Offers Telehealth

. Dr. Bagnato is rated as a Distinguished provider by MediFind in the treatment of Neuromyelitis Optica. Her top areas of expertise are Multiple Sclerosis (MS), Neuromyelitis Optica, Optic Neuritis, and Relapsing Multiple Sclerosis (RMS).

 
 
 
 
Learn about our expert tiers
Learn More
Donna Graves
Advanced in Neuromyelitis Optica
Advanced in Neuromyelitis Optica

Atrium Health Neurology Specialty Care

1225 Harding Place, Suite 4200, 
Charlotte, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Donna Graves is a Neurologist in Charlotte, North Carolina. Dr. Graves is rated as an Advanced provider by MediFind in the treatment of Neuromyelitis Optica. Her top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Neuromyelitis Optica, and Optic Neuritis. Dr. Graves is currently accepting new patients.

What are the latest Neuromyelitis Optica Clinical Trials?
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

Summary: Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact ...

Who are the sources who wrote this article ?

Published Date: March 01, 2015
Published By: National Institutes of Health